Maynard Um
-
-
-
-
-
-
-
Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at H.C. Wainwright
-
-
-
-
-
-
-
Lexicon submits additional data to FDA for Zynquista diabetes drug review
-
-
-
-
-
-
-
Lexicon Pharmaceuticals (LXRX) PT Raised to $0.85 at Jefferies
-
-
-
-
-
-
-
Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
-
-
-
-
-
-
-
Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
-
-
-
-
-
-
-
Lexicon Pharma (LXRX): New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)
-
466,483 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


